losartan has been researched along with transforming growth factor beta in 151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (12.58) | 18.2507 |
| 2000's | 71 (47.02) | 29.6817 |
| 2010's | 50 (33.11) | 24.3611 |
| 2020's | 11 (7.28) | 2.80 |
| Authors | Studies |
|---|---|
| Chevalier, RL; Chung, KH; Gomez, RA | 1 |
| Everett, AD; Fisher, A; Gomez, RA; Tufro-McReddie, A | 1 |
| Kopp, JB; Martínez-Maldonado, M; Montero, A; Pimentel, JL; Sundell, CL; Wang, S | 1 |
| DiPette, DJ; Wang, DH; Yao, A; Zhao, H | 1 |
| Kim, S | 1 |
| Espinosa, E; Liu, G; Lüscher, TF; Oemar, BS | 1 |
| Hostetter, TH; Junaid, A; Rosenberg, ME | 1 |
| Helmchen, U; Schneider, A; Stahl, RA; Wenzel, U; Wolf, G | 1 |
| Gardner, DG; Liang, F | 1 |
| Campbell, SE; Dhalla, AK; Kandala, JC; Katwa, LC; Sun, Y; Tyagi, SC; Weber, KT | 1 |
| Gomez, RA; Hilgers, KF; Pentz, ES | 1 |
| Ramires, FJ; Sun, Y; Zhang, J; Zhang, JQ | 1 |
| Border, WA; Noble, NA; Peters, H | 3 |
| Cerullo, G; Colucci, M; Gesualdo, L; Grandaliano, G; Monno, R; Ranieri, E; Rossiello, MR; Schena, FP; Semeraro, N; Ursi, M | 1 |
| Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F | 1 |
| Kim, HS; Oh, BH; Youn, TJ | 1 |
| Alavi, N; Leehey, DJ; Singh, AK; Singh, R | 1 |
| Lamparter, S; Sun, Y; Weber, KT | 1 |
| Chevalier, RL; Thornhill, BA; Yoo, KH | 1 |
| Dixon, IM; Hao, J; Reid, NL; Roth, JC | 1 |
| Bakhiet, M; Brauner, A; Burman, LG; Jaremko, G; Khalil, A; Tullus, K | 1 |
| Díez, J; Laviades, C; Varo, N | 1 |
| Dixon, IM; Hao, J; Jassal, DS; Jones, SC; Wang, B | 1 |
| Davidson, JM; Fogo, AB; Ma, LJ; Marcantoni, C; Nakamura, S; Whitsitt, JS | 1 |
| Bachireddy, P; Entman, M; Evans, A; Lim, DS; Lutucuta, S; Marian, AJ; Roberts, R; Youker, K | 1 |
| Bescós, M; Campistol, JM; Campos, B; Iñigo, P; Lario, S; Oppenheimer, F; Piera, C; Rivera, F | 1 |
| Campistol, JM; Esmatjes, E; Flores, L; Iñigo, P; Lario, S; Ruilope, LM | 1 |
| Bescos, M; Campistol, JM; Iñigo, P; Larios, S; Oppenheimer, F | 1 |
| Chen, H; Li, D; Mehta, JL | 1 |
| Carbini, LA; Nadal, JA; Scicli, AG; Scicli, GM | 1 |
| Han, HJ; Park, SH | 1 |
| Agarwal, R; Dunn, SR; Sharma, K; Siva, S | 1 |
| Akdeniz, A; Cooper, ME; Gilbert, RE; Houlihan, CA; Jerums, G; Tsalamandris, C | 1 |
| Ding, G; Franki, N; Gibbons, N; Kapasi, AA; Kasinath, BS; Reddy, K; Singhal, PC | 1 |
| Dai, C; Liu, Y; Yang, J | 1 |
| Gao, C; Lei, X; Mei, C; Zhou, C | 1 |
| Ahn, HJ; Bang, BK; Cha, JH; Jung, JY; Kim, J; Kim, WY; Kim, YS; Li, C; Yang, CW; Yoon, SA | 1 |
| Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG | 1 |
| Bottoms, SE; Chambers, RC; Gohlke, P; Howell, DC; Laurent, GJ; Marshall, RP; McAnulty, RJ; Unger, T | 1 |
| Cao, Z; Cooper, ME; Hu, L; Liu, J; Qin, J; Sun, L; Zhang, Z | 1 |
| Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F | 1 |
| Fujimiya, T; Naito, K; Shiraishi, K; Yoshida, K | 1 |
| Chan, LY; Chuang, TD; Guh, JY; Lai, KN; Lam, MF; Leung, JC; Tang, SC; Tsang, AW | 1 |
| Chen, WB; Fischer, JW; Kruse, ML; Petrik, C; Stoll, M; Stöter, K; Tiede, K; Ungefroren, H; Unger, T | 1 |
| Carrizo, L; Manucha, W; Oliveros, L; Seltzer, A; Vallés, P | 1 |
| Baker, KM; Booz, GW; Chernin, MI; Dostal, DE; Haiderzaidi, S; Kumar, R; Sanghi, S; Schreiber, T | 1 |
| Chung, HS; Han, SW; Kim, HJ; Kim, SW; Lee, JU; Paik, DJ; Paik, SS; Park, IK; Park, MH; Ryu, JH | 1 |
| Alvarellos, T; de Boccardo, G; Ferreira-Gonzalez, A; Maldonado, RA; Maluf, DG; Mas, VR; Oliveros, L | 1 |
| Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tokusashi, Y; Yokohama, S; Yoneda, M | 1 |
| Kolachana, P; Lawsin, LM; Moore, J; Perlman, A; Ringel, MD; Saji, M | 1 |
| Boner, G; Erman, A; Gafter, U; van Dijk, DJ; Veksler, S; Wittenberg, C | 1 |
| Lin, XH; Lindholm, B; Qian, JQ; Yao, Q | 1 |
| Jun, L; Qiang, CJ; Wei, YH | 1 |
| Bang, BK; Choi, BS; Kim, IS; Kim, YS; Lee, SH; Li, C; Lim, SW; Sun, BK; Yang, CW | 1 |
| Argano, C; Corrao, S; Di Chiara, T; Licata, A; Licata, G; Scaglione, R | 1 |
| Agharazii, M; Larivière, R; Lavoie, P; Lebel, M; Ledbetter, S; Robitaille, G | 1 |
| Akil, I; Gurcu, B; Inan, S; Muftuoglu, S; Nazikoglu, A; Ozbilgin, K | 1 |
| Chen, B; Chen, S; Huang, C; Ji, Z; Liang, C; Sun, W | 1 |
| Aldigier, JC; Brown, NJ; Fogo, AB; Kanjanbuch, T; Ma, LJ | 1 |
| Dikmen, T; Gul, S; Kaynar, K; Ovali, E; Ulusoy, S; Vanizor, B | 1 |
| Akgun, H; Dursun, N; Gunduz, Z; Koc, N; Okur, H; Ozturk, F | 1 |
| Cheng, L; Jiang, LQ; Krawczyk, M; Lakatta, EG; Monticone, R; Pintus, G; Spinetti, G; Talan, M; Wang, M; Zhang, J; Zhao, D | 1 |
| Lysiak-Szydlowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Wojnarowski, K | 1 |
| Carrizo, L; Manucha, W; Molina, H; Ruete, C; Vallés, P | 1 |
| Lu, Y; Yao, HW; Zhao, MH; Zhu, JP | 1 |
| Egido, J; García-Puig, J; Gómez-Garre, D; Granados, R; Martín-Ventura, JL; Ruano, M; Sancho, T; Torres, R | 1 |
| Aoshima, M; Aso, K; Haneda, M; Hasegawa, T; Miyokawa, N; Nakamura, K; Okada, M; Okamoto, S; Tamaki, Y; Tokusashi, Y; Yokohama, S; Yoneda, M | 1 |
| Travis, J | 1 |
| Bedja, D; Calvi, C; Carta, L; Cohn, RD; Cooper, TK; Dietz, HC; Gabrielson, K; Habashi, JP; Halushka, MK; Holm, TM; Huso, DL; Judge, DP; Klein, EC; Liu, G; Loeys, BL; Myers, L; Neptune, ER; Podowski, M; Ramirez, F; Rifkin, DB | 1 |
| Rodriguez-Iturbe, B | 1 |
| Kuehn, BM | 2 |
| Kakizoe, H; Sadamatsu, K; Seto, T; Shimokawa, H; Tashiro, H; Yamamoto, K | 1 |
| Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M | 1 |
| ap Rhys, CM; Cohn, RD; Dietz, HC; Gamradt, M; Habashi, JP; Holm, TM; Judge, DP; Klein, EC; Lisi, MT; Loeys, BL; Ramirez, F; Soleimani, AA; van Erp, C; Ward, CW | 1 |
| Chamberlain, JS | 1 |
| Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F | 1 |
| Ahn, SC; Baik, SK; Cho, MY; Choi, YH; Kim, CH; Kim, JW; Kim, MY; Kwon, SO; Park, DH; Rhim, DW | 1 |
| Cameron, DE; Carrel, T; Dietz, HC; Habashi, J; Matt, P; Van Eyk, JE | 1 |
| Brooke, BS; Dietz, HC; Habashi, JP; Judge, DP; Loeys, B; Patel, N | 1 |
| Pyeritz, RE | 1 |
| Han, Y; Kalluri, R | 1 |
| Aquilina, K; Hobbs, C; Thoresen, M; Tucker, A; Whitelaw, A | 1 |
| Liu, JS; Ning, WB; Tao, LJ; Wang, L; Xu, JY | 1 |
| Jiménez, SA; Rosenbloom, J | 1 |
| Meijers-Heijboer, H; Pals, G; van Dijk, FS | 1 |
| Amato, S; Arbustini, E; Dore, R; Favalli, V; Gambarin, FI; Klersy, C; Mannarino, S; Odero, A; Pasotti, M; Regazzi, M; Serio, A; Tavazzi, L; Viganò, M | 1 |
| Choo, JT; Lai, AH; Tan, TH; Wong, KY | 1 |
| Chum, E; Chung, AW; Kim, JM; van Breemen, C; Yang, HH | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Chang, A; Deb, DK; Kong, J; Li, YC; Zhang, Y | 1 |
| Casarini, DE; Coelho, MS; Ferreira, DN; Furukawa, LN; Heimann, JC; Katayama, IA; Oliveira, IB; Rosa, KT | 1 |
| Alcalai, R; Eminaga, S; Gorham, JM; Hoffman, SR; Kim, JB; Konno, T; Markwald, RR; Molkentin, JD; Nayor, M; Norris, RA; Schmitt, JP; Seidman, CE; Seidman, JG; Tager, AM; Teekakirikul, P; Toka, O; Wakimoto, H; Wang, L; Wolf, CM | 1 |
| Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S | 1 |
| Chan, LY; Guo, H; Lai, KN; Leung, JC; Tang, SC | 1 |
| Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q | 1 |
| Couzin-Frankel, J | 1 |
| Bedja, D; Chen, Y; Cohn, RD; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Kim, D; Lindsay, ME; Loeys, BL; Marugan, JJ; Patnaik, S; Schoenhoff, F; Thomas, CJ; van Erp, C | 1 |
| Aziz, H; Bedja, D; Chen, Y; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Modiri, AN; Schoenhoff, F | 1 |
| Fakhfakh, R; Lamarre, Y; Skuk, D; Tremblay, JP | 1 |
| Andres-Mateos, E; Burks, TN; Cohn, RD; Marx, R; Mejias, R; Simmers, JL; Van Erp, C; Walston, JD; Ward, CW | 1 |
| Ceci, L; Cheng, SH; Clayton, NP; Dinardo, CJ; Girgenrath, S; Hunter, RB; Keefe, KA; Leonard, JP; McCullough, JA; McVie-Wylie, A; Nelson, CA; Quigley, LA; Weber, WD; Wentworth, BM | 1 |
| Au, WS; Ho, YW; Lai, KN; Lin, M; Ma, MK; Tam, S; Tang, SC; Yap, DY | 1 |
| Bouhuizen, AM; Danser, AH; de Waard, MC; Duncker, DJ; Essers, J; Lankhorst, S; Moltzer, E; Ramnath, NW; Rouwet, EV; Swagemakers, SM; te Riet, L; van der Spek, PJ; van Esch, JH; van Heijningen, PM; van Veghel, R; Vermeij, M | 1 |
| Alvira, CM; Berry, GJ; Chin, JT; Dake, BA; Fischbein, MP; Iosef, C; Kimura, N; Maegdefessel, L; Merk, DR; Miller, MO; Mohr, FW; Robbins, RC; Spin, JM; Tsao, PS | 1 |
| Berger, A; Calvi, C; Cheadle, C; Dietz, HC; Ku, T; Lauer, T; Lopez-Mercado, A; McGrath-Morrow, S; Metzger, S; Misono, K; Mitzner, W; Neptune, E; Podowski, M; Poonyagariyagorn, H; Tuder, R; Wise, R | 1 |
| Azuma, J; Iekushi, K; Iwabayashi, M; Kusunoki, H; Morishita, R; Okayama, K; Otsu, R; Rakugi, H; Sanada, F; Taniyama, Y | 1 |
| Fu, X; Hu, G; Ning, W; Peng, Z; Tao, L; Wang, L; Wang, R; Wang, Z; Yuan, Q; Zhang, F | 1 |
| Arnold, SA; Bradshaw, AD; Brekken, RA; Carbon, JG; Chang, CL; Rivera, LB; Toombs, JE | 1 |
| Han, SY; Hong, IH; Jeong, KS; Ki, MR; Kim, AY; Kim, SJ; Kwon, SH; Lee, EJ; Lee, EM; Park, JK; Rando, TA; You, SY | 1 |
| Baxter, BT; Knispel, R; Meisinger, T; Worth, JM; Xiong, W | 1 |
| Cohn, RD; MacDonald, EM | 1 |
| Abbas, H; Ali, R; Geirsson, A; Hashim, S; Li, W; Sanchez, JA; Singh, M; Tellides, G | 1 |
| Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H | 1 |
| Chiou, TT; Hsu, CY; Huang, PC; Lee, CT; Lee, YT; Ng, HY; Tain, YL | 1 |
| ap Rhys, CM; Bedja, D; Calderon, JF; Chen, Y; Cooke, SK; Dietz, HC; Gallo, EM; Gerber, EE; Habashi, JP; Huso, DL; Judge, DP; Kent, KC; Lindsay, ME; Loch, DC; Myers, L; Norris, RA; Parker, SJ; Rouf, R; Sauls, K; van Erp, C | 1 |
| Andria, G; Brunetti-Pierri, N; Filocamo, M; Melis, D; Mithbaokar, P; Piccolo, P; Sabatino, V; Schiaffino, MC; Tolmie, J | 1 |
| Bischoff, J; Levine, RA; Wylie-Sears, J | 1 |
| Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L | 1 |
| Bar-Klein, G; Friedman, A; Heinemann, U; Kaufer, D; Parmet, Y; Serlin, Y | 1 |
| Cantilena, B; Cozzolino, C; Esposito, MT; Lombardo, B; Parisi, S; Passaro, F; Pastore, L; Querques, F; Russo, T | 1 |
| Carta, L; Cheng, SH; Chiu, E; Clayton, NP; Cook, JR; Galatioto, J; Nelson, CA; Ramirez, F; Smaldone, S; Wentworth, BM | 1 |
| Bruckner-Tuderman, L; Dengjel, J; Kern, JS; Kiritsi, D; Mittapalli, V; Nyström, A; Thriene, K | 1 |
| Jeong, KS; Kim, AY; Kim, DY; Kim, SH; Lee, EJ; Lee, EM; Lee, MM; Park, JK; Sung, SE | 1 |
| Antunes, E; Braga, GG; Costa, FTM; Dos Santos, L; Godoy, JA; Krieger, JE; Mendes, CB; Nery Diez, ACC; Pereira, DS; Vassequi-Silva, T; Vicente, CP; Werneck, CC | 1 |
| Lu, S; Ma, J; Peng, Z; Wu, M; Zhang, S; Zhong, J; Zu, C | 1 |
| Akazawa, H; Fujita, D; Fujiwara, T; Hara, H; Harada, M; Inuzuka, R; Komuro, I; Nawata, K; Takeda, N; Taniguchi, Y; Toko, H; Yagi, H | 1 |
| Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M | 1 |
| Milewicz, DM; Prakash, SK; Ramirez, F | 1 |
| Baek, CH; Chang, JW; Kim, H; Lee, RB; Lee, SK; Yang, WS | 1 |
| Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G | 1 |
| Adachi, H; Berkowitz, DE; Biswas, D; Das, S; Dunkerly-Eyring, B; Flavell, RA; Henao-Mejia, J; Hori, D; Nomura, Y; Santhanam, L; Steenbergen, C; Steppan, J | 1 |
| Becker, AJ; Friedman, A; Gu, F; Heinemann, U; Kaufer, D; Kim, SY; Lippmann, K; Milikovsky, DZ; Morrissey, CS; Parada, I; Prince, DA; Senatorov, VV; Vazquez, O | 1 |
| Aikawa, E; Bartko, PE; Beaudoin, J; Bischoff, J; Carpentier, A; Dal-Bianco, JP; Garcia, ML; Guerrero, JL; Hagège, AA; Handschumacher, MD; Irvin, WS; Kim, DH; Levine, RA; Messas, E; Seybolt, MM; Sullivan, S; Szymanski, C; Titus, JS; Wylie-Sears, J | 1 |
| Coimbra, TM; Costa, RS; da Silva, CGA; de Almeida, LF; Francescato, HDC | 1 |
| Bolia, I; Briggs, K; Huard, J; Lowe, WR; Philippon, MJ; Utsunomiya, H | 1 |
| Milewicz, DM; Ramirez, F | 1 |
| Bacino, CA; Brunetti-Pierri, N; Hicks, J; Mithbaokar, P; Piccolo, P; Polishchuk, E; Polishchuk, R; Sabatino, V | 1 |
| Dorotea, D; Ha, H; Jiang, S; Kim, DS; Oh, DS; Son, E | 1 |
| Hashimoto, T; Honda, K; Nobe, K; Shibata, K | 1 |
| Farinha-Arcieri, LE; Fernandes, GR; Gouveia, CH; Gyuricza, IG; Kawahara, EI; Lemes, RB; Miranda-Rodrigues, M; Neofiti-Papi, B; Pereira, LV; Reinhardt, DP; Souza, RB; Teixeira, MBCG | 1 |
| Chang, J; Du, J; Ge, X; Li, X; Li, YC; Liu, W; Nie, H; Sun, Y; Wei, X; Xun, Z | 1 |
| Axt-Fliedner, R; Del Nido, PJ; Dominguez, M; Friehs, I; Hammer, PE; Lin, RZ; Melero-Martin, JM; Vorisek, C; Weixler, V | 1 |
| Dobashi, S; Naito, H; Takaragawa, M; Yoshihara, T | 1 |
| Biedunkiewicz, B; Chamienia, A; Dębska-Ślizień, A; Głyda, M; Heleniak, Z; Konopa, J; Kuźmiuk-Glembin, I; Lizakowski, S; Pięta, R; Renke, M; Rutkowski, B; Tylicki, L | 1 |
| Abdollahimajd, F; Hajimoradi, B; Mansouri, P; Pourani, MR; Rakhshan, A; Uitto, J; Vahidnezhad, H; Youssefian, L | 1 |
| Ma, Y; Yu, R; Zhou, X; Zou, J | 1 |
| Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE | 1 |
| Wilson, SE | 1 |
10 review(s) available for losartan and transforming growth factor beta
| Article | Year |
|---|---|
[Role of the renin-angiotensin system in cardiovascular and renal diseases].
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Fibronectins; Gene Expression; Humans; Imidazoles; Kidney Diseases; Losartan; Proto-Oncogenes; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta | 1997 |
Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy.
Topics: Angiotensin II; Antihypertensive Agents; Biomarkers; Disease Progression; Endothelin-1; Humans; Kidney Transplantation; Losartan; Renin-Angiotensin System; Transforming Growth Factor beta; Transplantation, Homologous | 2001 |
Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Thoracic; Cohort Studies; Disease Models, Animal; Follow-Up Studies; Genetic Markers; Humans; Losartan; Marfan Syndrome; Mice; Microfilament Proteins; Risk Assessment; Survival Rate; Transforming Growth Factor beta; Treatment Outcome | 2008 |
TGFβ signaling: its role in fibrosis formation and myopathies.
Topics: Animals; Caveolin 3; Disease Models, Animal; Fibrosis; Humans; Losartan; MicroRNAs; Muscle, Skeletal; Muscular Diseases; Muscular Dystrophies; Sarcopenia; Signal Transduction; Transforming Growth Factor beta | 2012 |
Should losartan be administered following brain injury?
Topics: Animals; Blood-Brain Barrier; Brain; Brain Injuries; Humans; Losartan; Signal Transduction; Transforming Growth Factor beta | 2014 |
Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Disease Management; Fibrillin-1; Humans; Loeys-Dietz Syndrome; Losartan; Marfan Syndrome; Signal Transduction; Transforming Growth Factor beta | 2016 |
Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Disease Models, Animal; Genetic Predisposition to Disease; Humans; Losartan; Marfan Syndrome; Mechanoreceptors; Mice; Muscle, Smooth, Vascular; Signal Transduction; Transforming Growth Factor beta | 2017 |
Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.
Topics: Animals; Antifibrinolytic Agents; Cartilage; Disease Models, Animal; Fibrosis; Humans; Losartan; Muscle, Skeletal; Orthopedic Procedures; Platelet-Rich Plasma; Postoperative Complications; Tissue Adhesions; Transforming Growth Factor beta; Transforming Growth Factor beta1; Wound Healing | 2018 |
Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.
Topics: Acute Disease; Angiotensin II; Animals; Aortic Aneurysm, Thoracic; Aortic Dissection; Humans; Losartan; Mice; Signal Transduction; Transforming Growth Factor beta | 2019 |
Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cicatrix; Corneal Dystrophies, Hereditary; Corneal Injuries; Eye Diseases; Fibrosis; Humans; Losartan; Rabbits; Transforming Growth Factor beta | 2023 |
19 trial(s) available for losartan and transforming growth factor beta
| Article | Year |
|---|---|
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; Endothelins; Female; Fibrosis; Follow-Up Studies; Graft Rejection; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Losartan; Male; Middle Aged; Pilot Projects; Proteinuria; Transforming Growth Factor beta; Transplantation, Homologous; Vasoconstrictor Agents | 1999 |
Transforming growth factor beta in hypertensives with cardiorenal damage.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Collagen; Collagen Type I; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2000 |
Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Endothelin-1; Female; Hemodynamics; Humans; Kidney; Kidney Transplantation; Losartan; Male; Middle Aged; Renal Circulation; Renin; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2001 |
Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Pilot Projects; Systole; Transforming Growth Factor beta | 2001 |
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Kidney Failure, Chronic; Lisinopril; Losartan; Male; Middle Aged; Proteinuria; Transforming Growth Factor beta | 2002 |
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Sodium-Restricted; Female; Glycated Hemoglobin; Humans; Hypertension; Losartan; Male; Middle Aged; Placebos; Regression Analysis; Sodium; Transforming Growth Factor beta | 2002 |
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Glomerulonephritis, IGA; Humans; Hypertension; Losartan; Male; Middle Aged; Proteinuria; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2003 |
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus; Double-Blind Method; Female; Humans; Kidney Diseases; Losartan; Male; Middle Aged; Prospective Studies; Proteinuria; Transforming Growth Factor beta; Treatment Outcome | 2003 |
Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Humans; Kidney; Kidney Diseases; Kidney Transplantation; Losartan; Male; Middle Aged; Proteinuria; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Kidney; Losartan; Male; Middle Aged; Ramipril; Renal Insufficiency; Severity of Illness Index; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biomarkers; Creatinine; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Losartan; Male; Membrane Glycoproteins; Middle Aged; Nephelometry and Turbidimetry; Proteinuria; Renin-Angiotensin System; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Trypsin Inhibitor, Kunitz Soybean | 2005 |
Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Connective Tissue Growth Factor; Humans; Hypertension; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Losartan; Middle Aged; Reference Values; Transforming Growth Factor beta; Vascular Resistance | 2006 |
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cytokines; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Simvastatin; Transforming Growth Factor beta; Treatment Outcome | 2006 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; C-Reactive Protein; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Proteinuria; Transforming Growth Factor beta | 2006 |
Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Coagulation Factors; Blood Pressure; Cholesterol; Collagen Type IV; Creatine; Diabetes Mellitus, Type 2; Extracellular Matrix Proteins; Female; Fibronectins; Glycated Hemoglobin; Humans; Lipids; Losartan; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Potassium; Regression Analysis; Transforming Growth Factor beta; Treatment Outcome | 2006 |
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aorta; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Rate; Humans; Infant; Irbesartan; Linear Models; Losartan; Male; Marfan Syndrome; Prospective Studies; Tetrazoles; Transforming Growth Factor beta | 2008 |
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm; Benzopyrans; Child; Child, Preschool; Dilatation, Pathologic; Disease Progression; Ethanolamines; Female; Fibrillin-1; Fibrillins; Humans; Infant; Losartan; Male; Marfan Syndrome; Microfilament Proteins; Middle Aged; Mutation; Nebivolol; Quality of Life; Research Design; Time Factors; Transforming Growth Factor beta; Treatment Outcome; Young Adult | 2009 |
Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study.
Topics: Adult; Amides; Antihypertensive Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Fumarates; Glomerulonephritis, IGA; Hong Kong; Humans; Interleukin-6; Kidney Function Tests; Losartan; Male; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; Proteinuria; Risk Assessment; Severity of Illness Index; Time Factors; Transforming Growth Factor beta; Treatment Outcome; Urinalysis | 2012 |
Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients.
Topics: Albuminuria; Allografts; Biomarkers; Cardiovascular Diseases; Fibrosis; Heart Disease Risk Factors; Humans; Kidney Transplantation; Losartan; Potassium; Prospective Studies; Transforming Growth Factor beta | 2022 |
122 other study(ies) available for losartan and transforming growth factor beta
| Article | Year |
|---|---|
Regulation of renal growth factors and clusterin by AT1 receptors during neonatal ureteral obstruction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Blotting, Northern; Clusterin; DNA; Epidermal Growth Factor; Gene Expression; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycoproteins; Imidazoles; Kidney; Losartan; Molecular Chaperones; Nerve Tissue Proteins; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Reference Values; Renin; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Ureteral Obstruction | 1995 |
Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.
Topics: Angiotensin II; Animals; Aortic Coarctation; Atrial Natriuretic Factor; Biphenyl Compounds; Cardiomegaly; Gene Expression Regulation; Imidazoles; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles; Transforming Growth Factor beta | 1994 |
Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Gene Expression; Imidazoles; Immunohistochemistry; Kidney; Kidney Diseases; Losartan; Male; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Tissue Distribution; Transforming Growth Factor beta; Ureteral Obstruction | 1995 |
Regulation of ANG II receptor in hypertension: role of ANG II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Gene Expression; Hypertension; Imidazoles; Losartan; Male; Nephrectomy; Ramipril; Rats; Rats, Wistar; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta | 1996 |
Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells. Direct stimulation and indirect inhibition via transforming growth factor-beta 1.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cell Movement; Gene Expression; Humans; Imidazoles; Losartan; Muscle, Smooth, Vascular; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta | 1997 |
Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Culture Techniques; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Kidney; Kidney Glomerulus; Losartan; Male; Nephrectomy; Organ Size; Rats; Rats, Sprague-Dawley; Reference Values; RNA; Transforming Growth Factor beta | 1997 |
Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats.
Topics: Animals; Antihypertensive Agents; Drug Combinations; Hydralazine; Hydrochlorothiazide; Hypertension, Renovascular; Kidney; Kidney Glomerulus; Losartan; Male; Rats; Rats, Wistar; Reserpine; RNA, Messenger; Sclerosis; Time Factors; Transforming Growth Factor beta | 1998 |
Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes.
Topics: Angiotensin II; Animals; Antibodies; Autocrine Communication; Cells, Cultured; Culture Media, Conditioned; Endothelin-1; Gene Expression Regulation; Genes, Reporter; Humans; Losartan; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Paracrine Communication; Peptides, Cyclic; Promoter Regions, Genetic; Rats; RNA, Messenger; Sprains and Strains; Transfection; Transforming Growth Factor beta; Ventricular Function | 1998 |
Pouch tissue and angiotensin peptide generation.
Topics: Angiotensin I; Angiotensin II; Angiotensinogen; Angiotensins; Animals; Aspartic Acid Endopeptidases; Cathepsin D; Collagen; Gene Expression; Imidazoles; Lisinopril; Losartan; Myocardium; Peptide Biosynthesis; Peptides; Peptidyl-Dipeptidase A; Pyridines; Rats; Renin; Transforming Growth Factor beta | 1998 |
Angiotensin-dependent gene expression in the developing rat kidney.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Antihypertensive Agents; Blotting, Northern; Endothelial Growth Factors; Epidermal Growth Factor; Gene Expression Regulation, Developmental; Growth Substances; Kidney; Losartan; Lymphokines; Molecular Sequence Data; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart.
Topics: Angiotensin II; Animals; Collagen; Fibrosis; Losartan; Male; Myocardial Infarction; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; RNA, Messenger; Transforming Growth Factor beta | 1998 |
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Eating; Enalapril; Fibronectins; Fibrosis; Glomerulonephritis, Membranoproliferative; Kidney; Losartan; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta | 1998 |
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Antihypertensive Agents; Blotting, Northern; Cell Division; Cell Line, Transformed; Epithelial Cells; Fibrosis; Gene Expression; Humans; Kidney Diseases; Kidney Tubules, Proximal; Losartan; Peptides; Plasminogen Activator Inhibitor 1; Protease Inhibitors; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tissue Plasminogen Activator; Transforming Growth Factor beta; Urokinase-Type Plasminogen Activator | 1999 |
Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.
Topics: Angiotensin II; Animals; Enalapril; Glomerulonephritis; Losartan; Male; Rats; Rats, Sprague-Dawley; Thy-1 Antigens; Transforming Growth Factor beta | 1999 |
Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Echocardiography; Female; Hemodynamics; Losartan; Myocardial Infarction; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor beta; Ventricular Function, Left | 1999 |
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation.
Topics: Angiotensin II; Animals; Collagenases; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix; Glomerular Mesangium; Glucose; Losartan; Molecular Weight; Rats; Transforming Growth Factor beta | 1999 |
Angiotensin II receptor blockade during gestation attenuates collagen formation in the developing rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Birth Weight; Blotting, Western; Collagen; Female; Heart; Imidazoles; In Situ Hybridization; Losartan; Organ Size; Pregnancy; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor beta | 1999 |
Angiotensin stimulates TGF-beta1 and clusterin in the hydronephrotic neonatal rat kidney.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Clusterin; Glycoproteins; Imidazoles; Kidney; Losartan; Molecular Chaperones; Pyridines; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Ureteral Obstruction; Vasoconstrictor Agents | 2000 |
Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diet, Protein-Restricted; Enalapril; Glomerulonephritis; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Transforming Growth Factor beta; Treatment Outcome | 2000 |
Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blotting, Northern; Blotting, Western; Cardiomyopathy, Dilated; Collagen; Cricetinae; DNA-Binding Proteins; Female; Fluorescent Antibody Technique; Hydroxyproline; Losartan; Male; Matrix Metalloproteinases; Mesocricetus; Myocardium; RNA, Messenger; Signal Transduction; Smad2 Protein; Trans-Activators; Transforming Growth Factor beta | 2000 |
Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Down-Regulation; Female; Losartan; Mice; Mice, Inbred Strains; Pyelonephritis; RNA, Messenger; Transforming Growth Factor beta | 2000 |
Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cell Nucleus; Cells, Cultured; Collagen; Cytosol; DNA-Binding Proteins; Fibroblasts; Heart Failure; In Vitro Techniques; Losartan; Male; Myocardial Infarction; Myocardium; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Smad2 Protein; Smad4 Protein; Trans-Activators; Transforming Growth Factor beta; Vimentin | 2000 |
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
Topics: Aging; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Aorta, Thoracic; Apoptosis; Arteriosclerosis; Blood Pressure; Body Weight; Collagen; Creatinine; Gene Expression; In Situ Nick-End Labeling; Kidney Cortex; Kidney Diseases; Losartan; Male; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Sclerosis; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2000 |
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomyopathy, Hypertrophic; Collagen; Disease Models, Animal; Fibrosis; Humans; Losartan; Mice; Mice, Transgenic; Myocardium; Transforming Growth Factor beta; Transforming Growth Factor beta1; Troponin T | 2001 |
Angiotensin II via activation of type 1 receptor upregulates expression of endoglin in human coronary artery endothelial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antigens, CD; Cells, Cultured; Coronary Vessels; Endoglin; Endothelium, Vascular; Enzyme Inhibitors; Flavonoids; Humans; Losartan; Mitogen-Activated Protein Kinases; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; RNA, Messenger; Transcriptional Activation; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2001 |
Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB.
Topics: Angiotensin II; Animals; Antibodies; Anticoagulants; Antihypertensive Agents; Becaplermin; Cattle; Cells, Cultured; Chemotaxis; Dipeptides; Endothelial Growth Factors; Imidazoles; Losartan; Lymphokines; Matrix Metalloproteinase 2; Microcirculation; Neovascularization, Physiologic; Pericytes; Platelet-Derived Growth Factor; Protease Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Retina; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasoconstrictor Agents | 2002 |
The mechanism of angiotensin II binding downregulation by high glucose in primary renal proximal tubule cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Calcium Channel Blockers; Carcinogens; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression; Glucose; Imidazoles; Iodine Radioisotopes; Kidney Tubules, Proximal; Lipid Peroxidation; Losartan; Nifedipine; Oxidants; Oxidative Stress; Protein Kinase C; Protein Synthesis Inhibitors; Pyridines; Rabbits; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; RNA, Messenger; Tetradecanoylphorbol Acetate; Transforming Growth Factor beta; Vasoconstrictor Agents | 2002 |
Angiotensin II induces apoptosis in rat glomerular epithelial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Antihypertensive Agents; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Epithelial Cells; Fas Ligand Protein; fas Receptor; Imidazoles; Kidney Glomerulus; Losartan; Membrane Glycoproteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vasoconstrictor Agents | 2002 |
Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Drug Synergism; Fibroblasts; Fibrosis; Genetic Therapy; Hepatocyte Growth Factor; Humans; Kidney; Kidney Tubules; Losartan; Male; Mice; Mice, Inbred Strains; Muscle, Smooth; Receptor, Angiotensin, Type 1; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ureteral Obstruction | 2002 |
[Regulation of alpha(1) type I collagen promoter by cytokines and losartan].
Topics: Angiotensin II; Animals; Cells, Cultured; Chloramphenicol O-Acetyltransferase; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytokines; Gene Expression Regulation; Losartan; Promoter Regions, Genetic; Rats; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic Disease; Cyclosporine; Drug Synergism; Fibrosis; Gene Expression; Immunosuppressive Agents; Kidney; Kidney Diseases; Losartan; Macrophages; Male; Mycophenolic Acid; Osteopontin; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Angiotensin II and the fibroproliferative response to acute lung injury.
Topics: Acute Disease; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antihypertensive Agents; Bleomycin; Cell Division; Cells, Cultured; Collagen; Fibroblasts; Humans; Losartan; Lung; Peptidyl-Dipeptidase A; Procollagen; Pulmonary Fibrosis; Ramipril; Renin-Angiotensin System; Transforming Growth Factor beta | 2004 |
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Losartan; Male; Rats; Rats, Wistar; Simvastatin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2003 |
Angiotensin II dependent testicular fibrosis and effects on spermatogenesis after vasectomy in the rat.
Topics: Acetylcysteine; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Enalapril; Fibrosis; Heat-Shock Proteins; HSP47 Heat-Shock Proteins; Leydig Cells; Losartan; Male; Rats; Rats, Wistar; Spermatogenesis; Testis; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vasectomy | 2003 |
Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system.
Topics: Captopril; Cells, Cultured; Genes, ras; Glomerular Mesangium; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Losartan; Renin; Renin-Angiotensin System; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2003 |
Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro.
Topics: Angiotensin II; Animals; Animals, Newborn; Anti-Arrhythmia Agents; Autocrine Communication; Biglycan; Extracellular Matrix Proteins; Fibroblasts; Gene Expression; Losartan; Myocardial Infarction; Myocardium; Proteoglycans; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta | 2003 |
Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Cyclooxygenase 2; Female; Fibrosis; Gene Expression; Isoenzymes; Kidney; Kidney Diseases; Losartan; Nitric Oxide Synthase; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Transforming Growth Factor beta; Ureteral Obstruction | 2004 |
Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy.
Topics: Adenoviridae; Angiotensin II; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cell Membrane; Cytoskeleton; DNA Primers; Gene Expression Regulation; Insulin-Like Growth Factor I; Losartan; Mice; Myocytes, Cardiac; Rats; Receptor, Angiotensin, Type 1; Transforming Growth Factor beta; Vasoconstrictor Agents | 2004 |
Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cilazapril; Doxorubicin; Drug Interactions; Drug Synergism; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Losartan; Male; Nephrosis, Lipoid; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Topics: Adult; Angiotensin Receptor Antagonists; Biomarkers; Fatty Liver; Female; Ferritins; Hepatitis; Humans; Hypertension; Iron; Liver; Liver Cirrhosis; Losartan; Male; Middle Aged; Necrosis; Osmolar Concentration; Transaminases; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Angiotensin II regulation of TGF-beta in murine mesangial cells involves both PI3 kinase and MAP kinase.
Topics: Angiotensin II; Animals; Butadienes; Cell Line; Chromones; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Epidermal Growth Factor; Glomerular Mesangium; Immunoblotting; Losartan; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta; Tyrphostins | 2004 |
Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Drug Synergism; Enalapril; Hypertrophy; Kidney; Losartan; Male; Proteinuria; Rats; Rats, Wistar; Renin-Angiotensin System; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Cells, Cultured; Dialysis Solutions; DNA-Binding Proteins; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Genes, Tumor Suppressor; Glucose; Humans; Losartan; Mannitol; Peritoneal Cavity; Peritoneal Dialysis; RNA, Messenger; Signal Transduction; Smad2 Protein; Trans-Activators; Transforming Growth Factor beta; Up-Regulation | 2004 |
Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.
Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Liver Cirrhosis; Losartan; Male; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2004 |
Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Northern; Cyclosporine; Disease Models, Animal; Extracellular Matrix Proteins; Immunoblotting; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization; Losartan; Male; Nephritis, Interstitial; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation | 2005 |
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta, Thoracic; Blood Pressure; Blotting, Northern; Blotting, Western; Creatinine; Endothelin-1; Gene Expression; Hypertension; Kidney; Losartan; Male; Neutralization Tests; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Uremia | 2005 |
Histopathological and ultrastructural effects of Losartan on embryonic rat kidney.
Topics: Animals; Apoptosis; Disease Models, Animal; Epithelial Cells; Female; Glomerular Basement Membrane; Immunohistochemistry; Kidney; Kidney Tubules; Losartan; Male; Microscopy, Confocal; Microscopy, Electron; Nephrons; Pregnancy; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Transforming Growth Factor beta | 2005 |
Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Benzazepines; Collagen Type IV; DNA, Complementary; Endothelin-1; Fibronectins; Glomerulosclerosis, Focal Segmental; Kidney; Losartan; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Regression of existing glomerulosclerosis by inhibition of aldosterone.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephritis; Kidney Function Tests; Losartan; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Spironolactone; Transcription, Genetic; Transforming Growth Factor beta | 2005 |
TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture.
Topics: Amlodipine; Antihypertensive Agents; Atherosclerosis; Cells, Cultured; Humans; Leukocytes, Mononuclear; Losartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2005 |
Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Creatinine; Kidney; Kidney Diseases; Leptin; Losartan; Proteinuria; Rats; Rats, Wistar; Renin-Angiotensin System; Sodium; Transforming Growth Factor beta; Transforming Growth Factor beta1; Urination | 2005 |
Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.
Topics: Adrenergic alpha-Agonists; Aging; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Carotid Arteries; Collagen; Dipeptides; Immunohistochemistry; Losartan; Male; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Organ Culture Techniques; Phenylephrine; Protease Inhibitors; Rats; RNA, Messenger; Transcription, Genetic; Transforming Growth Factor beta; Tunica Intima; Vasoconstrictor Agents | 2005 |
Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Female; Fibrosis; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Hydroxyl Radical; Immunohistochemistry; Kidney Cortex; Losartan; Oxidative Stress; Rats; Rats, Inbred WKY; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxide Dismutase; Transforming Growth Factor beta; Ureteral Obstruction | 2005 |
Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Bleomycin; Body Weight; Glucocorticoids; Hydroxyproline; Losartan; Lung; Male; Malondialdehyde; Prednisone; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Transforming Growth Factor beta; Transforming Growth Factor beta1; Weight Gain | 2006 |
Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Losartan; Male; Middle Aged; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Medicine. Old drug, new hope for Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm; Clinical Trials as Topic; Disease Models, Animal; Emphysema; Fibrillins; Humans; Losartan; Marfan Syndrome; Mice; Microfilament Proteins; Mutation; Transforming Growth Factor beta | 2006 |
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Aorta; Aortic Aneurysm; Disease Models, Animal; Elastic Tissue; Female; Fibrillin-1; Fibrillins; Losartan; Lung; Lung Diseases; Marfan Syndrome; Mice; Microfilament Proteins; Mutation; Neutralization Tests; Pregnancy; Pregnancy Complications; Propranolol; Pulmonary Alveoli; Receptor, Angiotensin, Type 1; Signal Transduction; Transforming Growth Factor beta | 2006 |
Arteriolar remodeling in essential hypertension: are connective tissue growth factor and transforming growth factor involved?
Topics: Amlodipine; Antihypertensive Agents; Arterioles; Connective Tissue Growth Factor; Humans; Hypertension; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Losartan; Transforming Growth Factor beta | 2006 |
Drug shows promise for marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Fibrillins; Humans; Losartan; Marfan Syndrome; Microfilament Proteins; Transforming Growth Factor beta | 2006 |
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Fibrillin-1; Fibrillins; Fluorescent Antibody Technique; Histocytochemistry; Losartan; Marfan Syndrome; Mice; Microfilament Proteins; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Mutation; Regeneration; Signal Transduction; Transforming Growth Factor beta | 2007 |
ACE inhibitor bulks up muscle.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Losartan; Marfan Syndrome; Mice; Models, Biological; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Regeneration; Signal Transduction; Transforming Growth Factor beta | 2007 |
[Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats].
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Bile Ducts; Captopril; Fibrosis; Hydroxyproline; Ligation; Liver; Liver Cirrhosis, Experimental; Losartan; Male; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta | 2007 |
Studies point way to new therapeutic prospects for muscular dystrophy.
Topics: Animals; Codon, Nonsense; Dystrophin; Gene Expression; Humans; Losartan; Marfan Syndrome; Mice; Muscular Dystrophy, Duchenne; Oxadiazoles; PPAR alpha; Transforming Growth Factor beta | 2007 |
A small molecule for a large disease.
Topics: Angiotensin II Type 1 Receptor Blockers; History, 20th Century; Humans; Losartan; Marfan Syndrome; Transforming Growth Factor beta | 2008 |
Targeting TGF-beta and the extracellular matrix in Marfan's syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Child; Disease Progression; Extracellular Matrix; Fibrillins; Genes, Dominant; Humans; Losartan; Marfan Syndrome; Microfilament Proteins; Mutation; Radiography; Signal Transduction; Transforming Growth Factor beta | 2008 |
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Dilatation, Pathologic; Disease Models, Animal; Losartan; Pyridones; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta | 2008 |
[The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy].
Topics: Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerulosclerosis, Focal Segmental; Losartan; Male; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta | 2008 |
Angiotensin II blockade in Marfan's syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzamides; Fibrillins; Humans; Imatinib Mesylate; Losartan; Marfan Syndrome; Microfilament Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Transforming Growth Factor beta | 2008 |
Angiotensin II blockade in Marfan's syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Child; Fibrillins; Humans; Losartan; Marfan Syndrome; Microfilament Proteins; Mutation; Transforming Growth Factor beta | 2008 |
Loeys-Dietz syndrome: a Marfan-like syndrome associated with aggressive vasculopathy.
Topics: Anti-Arrhythmia Agents; Aortic Aneurysm; Echocardiography; Female; Humans; Infant, Newborn; Loeys-Dietz Syndrome; Losartan; Marfan Syndrome; Risk; Time Factors; Transforming Growth Factor beta | 2009 |
Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Disease Models, Animal; Doxycycline; Drug Synergism; Drug Therapy, Combination; Elastic Tissue; Fibrillin-1; Fibrillins; Losartan; Marfan Syndrome; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Microfilament Proteins; Phosphorylation; Protease Inhibitors; Secondary Prevention; Smad2 Protein; Time Factors; Transforming Growth Factor beta; Vasoconstriction; Vasodilation | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.
Topics: Angiotensin I; Animals; Cells, Cultured; Chemokine CCL2; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Fibronectins; Fibrosis; Kidney; Kidney Diseases; Losartan; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Calcitriol; Renin-Angiotensin System; Transforming Growth Factor beta | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Collagen Type I; Collagen Type III; Disease Models, Animal; Drinking; Eating; Echocardiography; Fibrosis; Gene Expression; Heart Ventricles; Hydralazine; Hypertension; Losartan; Male; Myocardium; Potassium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Renin-Angiotensin System; Sodium; Sodium Chloride, Dietary; Transforming Growth Factor beta; Urine | 2010 |
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β.
Topics: Animals; Bromodeoxyuridine; Cardiomyopathy, Hypertrophic; Cell Proliferation; Disease Models, Animal; Fibrosis; Losartan; Mice; Mutation; Myocardium; Myocytes, Cardiac; Sarcomeres; Signal Transduction; Transforming Growth Factor beta | 2010 |
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Bone Resorption; Disease Models, Animal; Fibrillin-1; Fibrillins; Losartan; Marfan Syndrome; Mice; Mice, Inbred C57BL; Microfilament Proteins; Mutation; Osteoblasts; Osteoclasts; Osteogenesis; Spine; Tomography, X-Ray Computed; Transforming Growth Factor beta | 2010 |
Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Therapy, Combination; gamma-Globulins; Glomerulonephritis, IGA; Intercellular Adhesion Molecule-1; Kidney; Leukocytes, Mononuclear; Losartan; Mesangial Cells; Nephrectomy; PPAR gamma; Proteinuria; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta | 2011 |
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Cell Adhesion Molecules; Dystrophin; Female; Fibrosis; Gene Expression Regulation; Heart; Losartan; Mice; Mice, Inbred mdx; Muscle Weakness; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Myocardium; RNA, Messenger; Thrombospondin 1; Transforming Growth Factor beta | 2011 |
Medicine. Frightening risk of Marfan syndrome, and potential treatment, elucidated.
Topics: Animals; Aortic Aneurysm; Clinical Trials as Topic; Extracellular Signal-Regulated MAP Kinases; Humans; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Mice; Protein Kinase Inhibitors; Signal Transduction; Transforming Growth Factor beta | 2011 |
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progression; Enzyme Activation; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Protein Kinase Inhibitors; Smad2 Protein; Smad4 Protein; Sulfonamides; Transforming Growth Factor beta | 2011 |
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Aortic Aneurysm; Aortic Rupture; Disease Models, Animal; Disease Progression; Enalapril; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptor, Angiotensin, Type 2; Signal Transduction; Transforming Growth Factor beta | 2011 |
Losartan enhances the success of myoblast transplantation.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Cell Transplantation; Cells, Cultured; Dystrophin; Graft Survival; Humans; Losartan; Macrophage Activation; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Dystrophy, Animal; Myoblasts; Transforming Growth Factor beta | 2012 |
Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.
Topics: Angiotensin Receptor Antagonists; Animals; Insulin-Like Growth Factor I; Losartan; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Disorders, Atrophic; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Sarcopenia; Signal Transduction; TOR Serine-Threonine Kinases; Transforming Growth Factor beta | 2011 |
Inhibiting TGF-β activity improves respiratory function in mdx mice.
Topics: Animals; Biomarkers; Body Weight; Cell Adhesion Molecules; Creatine Kinase; Diaphragm; Dose-Response Relationship, Drug; Enalapril; Gene Expression Regulation; Hand Strength; Hydroxyproline; Inflammation; Losartan; Mice; Mice, Inbred mdx; Muscle Fibers, Skeletal; Myogenin; Organ Size; Respiration; Respiratory Function Tests; RNA, Messenger; Transforming Growth Factor beta | 2011 |
Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aorta, Thoracic; Aortic Aneurysm; Extracellular Matrix Proteins; Female; Humans; Immunohistochemistry; In Vitro Techniques; Losartan; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Phenylephrine; Pregnancy; Receptor, Angiotensin, Type 1; Smad2 Protein; Transcriptome; Transforming Growth Factor beta; Vasoconstriction; Vasoconstrictor Agents | 2011 |
miR-29b participates in early aneurysm development in Marfan syndrome.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Apoptosis; Apoptosis Regulatory Proteins; Cells, Cultured; Disease Models, Animal; Elastin; Female; Fibrillin-1; Fibrillins; Genetic Therapy; Losartan; Male; Marfan Syndrome; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; MicroRNAs; NF-kappa B; Oligonucleotides, Antisense; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Up-Regulation | 2012 |
Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Disease Models, Animal; Humans; Losartan; Lung; Male; Mice; Mice, Inbred AKR; Pulmonary Disease, Chronic Obstructive; Receptor, Angiotensin, Type 1; Respiratory Mechanics; Signal Transduction; Smoking; Transforming Growth Factor beta | 2012 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; Fibroblasts; Hepatocyte Growth Factor; Hydronephrosis; Kidney; Losartan; Male; Mice; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Ureteral Obstruction | 2012 |
Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Cell Line; Connective Tissue Growth Factor; Epithelial Cells; Epithelial-Mesenchymal Transition; Fibronectins; Fluorescent Antibody Technique; Humans; Indicators and Reagents; Kidney Tubules, Proximal; Losartan; Pyridones; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2011 |
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Extracellular Matrix; Losartan; Mice; Mice, Knockout; Neoplasm Invasiveness; Neoplasm Metastasis; Osteonectin; Pancreatic Neoplasms; Survival Rate; Transforming Growth Factor beta; Treatment Outcome | 2012 |
Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-β and fibrosis in skeletal muscle injury.
Topics: Adipose Tissue; Animals; Coculture Techniques; Fibrosis; Immunoblotting; Losartan; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; Reverse Transcriptase Polymerase Chain Reaction; Satellite Cells, Skeletal Muscle; Stem Cell Niche; Transforming Growth Factor beta | 2012 |
MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome.
Topics: Animals; Aorta, Thoracic; Disease Progression; Doxycycline; Drug Therapy, Combination; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Phosphorylation; Transforming Growth Factor beta; Vasodilation | 2012 |
Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Cells, Cultured; Collagen; Elastic Tissue; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Genetic Diseases, X-Linked; Heart Defects, Congenital; Humans; Losartan; Mitral Valve Insufficiency; Mitral Valve Prolapse; Myxoma; Polymerase Chain Reaction; Signal Transduction; Smad2 Protein; Smad3 Protein; Telmisartan; Tetrazoles; Transforming Growth Factor beta; Vimentin | 2012 |
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models, Animal; Disease Progression; DNA Primers; Dose-Response Relationship, Drug; Fatty Liver; Gene Expression; Hepatic Stellate Cells; Liver Cirrhosis; Losartan; Male; NF-kappa B; Non-alcoholic Fatty Liver Disease; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Toll-Like Receptor 4; Transforming Growth Factor beta | 2013 |
Renin angiotensin system blockade ameliorates lead nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Gene Expression Regulation; Glomerular Filtration Rate; Kidney Diseases; Lead Poisoning; Losartan; Male; Peptidyl-Dipeptidase A; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Transforming Growth Factor beta | 2013 |
Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Cells, Cultured; Disease Progression; Female; Haploinsufficiency; Humans; Loeys-Dietz Syndrome; Losartan; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Mutation, Missense; Myocytes, Smooth Muscle; Phenotype; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta | 2014 |
SMAD4 mutations causing Myhre syndrome result in disorganization of extracellular matrix improved by losartan.
Topics: Adolescent; Adult; Child; Cryptorchidism; Extracellular Matrix; Facies; Female; Fibroblasts; Growth Disorders; Hand Deformities, Congenital; Humans; Hypertrophy; Intellectual Disability; Joint Diseases; Losartan; Metalloendopeptidases; Microfibrils; Mutation; Phosphorylation; Signal Transduction; Smad2 Protein; Smad4 Protein; Transforming Growth Factor beta; Young Adult | 2014 |
Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Endothelial Cells; Epithelial-Mesenchymal Transition; Losartan; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitral Valve; Phosphorylation; Receptors, Angiotensin; Recombinant Proteins; Sheep; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta | 2014 |
Losartan prevents acquired epilepsy via TGF-β signaling suppression.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Benzamides; Blood-Brain Barrier; Cells, Cultured; Cerebral Cortex; Dioxoles; Disease Models, Animal; Embryo, Mammalian; Endocytosis; Epilepsy; Losartan; Male; Neurons; Phosphopyruvate Hydratase; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor beta | 2014 |
Angiotensin receptor I stimulates osteoprogenitor proliferation through TGFβ-mediated signaling.
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensins; Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Humans; Imidazoles; Losartan; Mesenchymal Stem Cells; Mice; Osteoblasts; Pyridines; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta | 2015 |
Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Neutralizing; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic Rupture; Disease Models, Animal; Disease Progression; Fibrillin-1; Fibrillins; Humans; Losartan; Marfan Syndrome; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Mutant Strains; Microfilament Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Receptor, Angiotensin, Type 1; Signal Transduction; Smad2 Protein; Time Factors; Transforming Growth Factor beta | 2015 |
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
Topics: Animals; Disease Models, Animal; Epidermolysis Bullosa Dystrophica; Immunologic Factors; Inflammation; Losartan; Mice; Proteome; Transforming Growth Factor beta; Treatment Outcome | 2015 |
Chronic effects of losartan on the muscles and the serologic profiles of mdx mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Losartan; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Transforming Growth Factor beta; Treatment Outcome | 2015 |
Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice.
Topics: Animals; Antihypertensive Agents; Captopril; Carotid Arteries; Contractile Proteins; Extracellular Matrix Proteins; Gelatinases; Gene Deletion; Losartan; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Platelet Function Tests; RNA Splicing Factors; Thrombosis; Transforming Growth Factor beta | 2016 |
Losartan Attenuates Myocardial Endothelial-To-Mesenchymal Transition in Spontaneous Hypertensive Rats via Inhibiting TGF-β/Smad Signaling.
Topics: Animals; Blood Pressure; Blotting, Western; Body Weight; Calcium-Binding Proteins; Collagen Type I; Electrocardiography; Endothelium; Heart Rate; Heart Ventricles; Losartan; Mesoderm; Microscopy, Confocal; Myocardium; Organ Size; Platelet Endothelial Cell Adhesion Molecule-1; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Smad Proteins; Staining and Labeling; Transforming Growth Factor beta | 2016 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Interleukin-6; Interleukin-8; Iran; Losartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
Anti-Fibrotic Effect of Losartan, an Angiotensin II Receptor Blocker, Is Mediated through Inhibition of ER Stress via Up-Regulation of SIRT1, Followed by Induction of HO-1 and Thioredoxin.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Epithelial Cells; Gene Expression; Heme Oxygenase-1; Kidney Diseases; Losartan; Mice; Sirtuin 1; Thioredoxins; Transforming Growth Factor beta; Tunicamycin | 2017 |
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibrosis; Humans; Losartan; Male; Myocardium; Myofibroblasts; Protein-Lysine 6-Oxidase; Rats; Rats, Wistar; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2017 |
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling.
Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cardiovascular Diseases; Endothelial Cells; Extracellular Matrix; Hypertension; Losartan; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Nitric Oxide; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Vascular Stiffness | 2017 |
TGFβ signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults.
Topics: Astrocytes; Blood-Brain Barrier; Brain Injuries, Traumatic; Cerebral Cortex; Computational Biology; Extracellular Matrix; Gene Expression; Gene Expression Profiling; Hippocampus; Humans; Inflammation; Interneurons; Losartan; Neurons; Receptor, Transforming Growth Factor-beta Type I; Signal Transduction; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta | 2017 |
Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography, Three-Dimensional; Endothelial Cells; Fibrosis; Humans; Losartan; Mitral Valve; Mitral Valve Insufficiency; Myocardial Infarction; Papillary Muscles; Sheep; Transforming Growth Factor beta; Ventricular Remodeling | 2017 |
Calcitriol reduces kidney development disorders in rats provoked by losartan administration during lactation.
Topics: Animals; Biomarkers; Biopsy; Blood Pressure; Body Weight; Breast Feeding; Calcitriol; Chemokine CCL2; Congenital Abnormalities; Disease Models, Animal; Female; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Lactation; Losartan; Male; Rats; Transforming Growth Factor beta | 2017 |
Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect.
Topics: Adolescent; Bone Diseases, Developmental; Child; Child, Preschool; Extracellular Matrix; Female; Fibrillin-1; Fibroblasts; Humans; Infant; Limb Deformities, Congenital; Losartan; Lysosomes; Male; Microfibrils; Signal Transduction; Skin; Transforming Growth Factor beta | 2019 |
Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk.
Topics: Animals; Cell Line; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney Diseases; Kidney Tubules; Losartan; Male; Medicine, Chinese Traditional; Medicine, Korean Traditional; Mice, Inbred C57BL; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Transforming Growth Factor beta; Ureteral Obstruction | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; Losartan; Male; Membrane Proteins; Metabolic Clearance Rate; Mice, Inbred Strains; Nephrectomy; Renal Insufficiency, Chronic; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2021 |
Hyperkyphosis is not dependent on bone mass and quality in the mouse model of Marfan syndrome.
Topics: Animals; Female; Fibrillin-1; Kyphosis; Losartan; Male; Marfan Syndrome; Mice; Transforming Growth Factor beta | 2021 |
Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Bleomycin; Disease Models, Animal; Ergocalciferols; Losartan; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Pulmonary Fibrosis; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Transforming Growth Factor beta; Vitamin D | 2021 |
Mechanical strain triggers endothelial-to-mesenchymal transition of the endocardium in the immature heart.
Topics: Animals; Bone Morphogenetic Protein 7; Endocardial Fibroelastosis; Endocardium; Endothelial Cells; Epithelial-Mesenchymal Transition; Losartan; Rats; Signal Transduction; Transcription Factors; Transforming Growth Factor beta | 2022 |
Losartan treatment attenuates hindlimb unloading-induced atrophy in the soleus muscle of female rats via canonical TGF-β signaling.
Topics: Animals; Female; Hindlimb; Hindlimb Suspension; Losartan; Male; Muscle, Skeletal; Muscular Atrophy; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor beta | 2022 |
Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Topics: Animals; Cicatrix; Collagen; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Female; Losartan; Male; Mice; Quality of Life; Transforming Growth Factor beta | 2022 |
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad.
Topics: Animals; Fibrosis; Kidney; Kidney Diseases; Losartan; Male; Metabolic Networks and Pathways; Mice; Mice, Inbred C57BL; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ureteral Obstruction | 2022 |
Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.
Topics: Animals; Collagen Type IV; Fibrosis; Losartan; Rabbits; Transforming Growth Factor beta; United States | 2022 |